While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily toward branded drugmakers, generic medicines and the companies that ...
Novartis (NYSE:NVS) is suing the U.S. FDA as well as HHS over what it claims was the agency's unlawful approval of a generic of its blockbuster heart failure drug Entresto. The complaint, filed July ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback